Also trades as: ODTC (OTC) · $vol 0M
ODT NASDAQ
Odonate Therapeutics, Inc.
1W: +2.8%
1M: -24.3%
3M: -62.9%
1Y: -94.4%
3Y: -93.2%
$1.12
Last traded 2022-01-14 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$0.0M
52W Range1.1107-1.2
Volume716,440
Avg Volume959,817
Beta0.45
Dividend—
Analyst Ratings
Company Info
CEOKevin Tang
Employees137
SectorHealthcare
IndustryBiotechnology
IPO Date2017-12-07
Websiteodonate.com
4747 Executive Dr Ste 510
San Diego, CA 10016
US
San Diego, CA 10016
US
18582003830
About Odonate Therapeutics, Inc.
Odonate Therapeutics, Inc. functions as a pharmaceutical enterprise, dedicating its efforts to the creation of innovative therapeutic agents for cancer treatment. A prominent compound within its development pipeline is tesetaxel, an orally administered chemotherapy drug. This agent is currently advancing through Phase III clinical trials, specifically under investigation for its application in individuals with metastatic breast cancer. Established in 2013, the company's operations are headquartered in New York, New York.
Latest News
No recent news
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| EcoR1 Capital, LLC | S-Sale | 5,000,000 | $1.66 | 2021-12-10 |
| EcoR1 Capital, LLC | S-Sale | 545,000 | $1.55 | 2021-12-10 |
| EcoR1 Capital, LLC | S-Sale | 156,669 | $1.82 | 2021-12-09 |
| EcoR1 Capital, LLC | S-Sale | 185,941 | $1.66 | 2021-12-01 |
| EcoR1 Capital, LLC | P-Purchase | 185,941 | $1.66 | 2021-12-01 |